A5071842464- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Glioma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
- Venous Thromboembolism Diagnosis and Management
- Acute Myocardial Infarction Research
- Chronic Lymphocytic Leukemia Research
- Blood Coagulation and Thrombosis Mechanisms
- Sarcoma Diagnosis and Treatment
- Down syndrome and intellectual disability research
- Vascular Malformations Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Mechanisms and Therapy
- Ion channel regulation and function
- Rheumatoid Arthritis Research and Therapies
- Testicular diseases and treatments
- Neuroendocrine Tumor Research Advances
Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology
2017-2024
Ministry of Health of the Russian Federation
2021-2024
Ministry of Health
2019-2022
Belarusian Research Center For Pediatric Oncology and Hematology
2019-2022
N.N. Alexandrov National Cancer Centre
2022
Republican Scientific and Practical Center of Neurology and Neurosurgery
2018-2021
MRC Laboratory of Molecular Biology
2005
Favorable outcomes were achieved for children with acute lymphoblastic leukemia (ALL) the first Russian multicenter trial Moscow–Berlin (ALL-MB) 91. One major component of this regimen included a total 18 doses weekly intramuscular (IM) native Escherichia coli-derived asparaginase (E. coli-ASP) at 10000 U/m2 during three consolidation courses. ASP was initially available from Latvia, but had to be purchased abroad substantial costs after collapse Soviet Union. Therefore, subsequent ALL-MB...
One of the main risk-factors acute lymphoblastic leukemia (ALL) is age. The most favorable age group children from 2 to 9 years old, and adolescents young adults have worst prognosis. Treatment ALL at a unique problem modern hematology now. This work presents analysis 368 cases patients with primary 15–18 which were registered in database Russian-Belarussian April 2002 November 2014. aim was estimation effectiveness different generations protocol for prognostic significance factors reveal...
The prognostic significance of genetic lesions in T-cell ALL still needs to be elucidated. Karyotyping and FISH were performed samples from 120 patients with registered the trial Moscow-Berlin 2008. Most frequent rearrangements TLX3 (N = 29; 24%) TAL1 18; 15%), followed by KMT2A 6; 5%), TLX1 5; 4.2%), 11p13-15 4.2%). In 16.7% patients, karyotype was normal, 30.8% 'other' aberrations seen. Patients a normal karyotype, TAL1, or had most favorable outcome (probability event free survival...
Down syndrome (DS) is one of the most common chromosomal abnormalities. Children with DS are more likely to develop acute lymphoblastic leukemia (ALL). Standard therapy usually used treat DS-ALL, but children DS-ALL have an inferior outcome compared non-DS patients, mainly due increased toxicity. The purpose study: in this study we aimed analyze our experience treating according original protocol “Moscow–Berlin”. This supported by Independent Ethics Committee and approved Academic Council...
Introduction . Down syndrome (DS) is one of the most common chromosomal abnormalities. Children with DS have an increased risk developing acute lymphoblastic leukemia (ALL). Standard therapy usually used to treat ALL in children syndrome, but outcome worse than general population. The high toxicity a particular problem. purpose study – this we presents comparative analysis results for and (DS-ALL) who received according ALL-MB 2008 2015 protocols. Materials methods included primary patients,...
The relapse of acute lymphoblastic leukemia (ALL) in children is still a difficult task. This due both to the difficulties achieving a second remission and problems organizing allogeneic bone marrow transplantation (BMT) those patients who need it. standard approach use second-line drugs regime high-dosage chemotherapy blocks, but response rate for this treatment with early relapses remains low response time short. Recently, new drugs with different mechanisms action have appeared that...
The bispecific monoclonal antibody blinatumomab (CD19/CD3) is widely and successfully used to treat children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Advances have also led the use of immunotherapy in primary BCP-ALL. This paper presents effectiveness a single course instead consolidation chemotherapy short maintenance therapy BCP-ALL patients. study was approved by Independent Ethics Committee Scientific Council Dmitry Rogachev National Medical...
Children with acute lymphoblastic leukemia (ALL) and slow clearance of minimal residual disease (MRD) demonstrate a significantly worse outcome as compared to those fast response chemotherapy. Bispecific monoclonal antibody blinatumomab is the key drug for CD19-directed immunotherapy which opens wide opportunities elimination MRD in patients B-cell precursor ALL (BCP-ALL). Aim study – evaluate effectiveness children BCP-ALL treated by “ALL-MB 2015” protocol. The was approved Independent...
The achievement of remission at the end induction (EOI) chemotherapy in patients with acute lymphoblastic leukemia (ALL) is key parameter treatment effectiveness evaluation. aim study – defining complete by multicolor flow cytometry (MFC) and bone marrow (BM) cytomorphology (CM) EOI children B-lineage ALL. was approved Independent Ethics Committee Scientific Council Dmitry Rogachev National Medical Research Center Pediatric Hematology, Oncology Immunology. included “ALL-MB 2008” 2015” trials...
Introduction . Neuroblastoma (NB) in children is a rare disease, accounting for 7 % of all cases oncological diseases childhood. In this regard, epidemiological analysis requires the accumulation data over long period time. The purpose study to morbidity, mortality and survival rate 0–14 years old with NB Republic Belarus (RB). Materials methods Based on from children’s cancer subregister, rates child population were calculated 1997 2017. A comparative was carried out 2 time periods...
Despite remarksble improvements in the treatment of pediatric acute limphoblastic leukemia (ALL) over last decades, relapse still caries a poor prognosis with considerable morbidity and mortality. New strategies approaches are extremely needed. According to results previous protocol ALL-REZ-2014 despite implementation bortezomib, as well idarubicin navelbine, which have not been used first-line therapy, new had demonstrated no significant improvement reaching steady remission, especially for...
T-cell acute lymphoblastic leukemia (T-ALL) is a tumor developing as result of malignant transformation precursor T-cells. Despite the fact that T-ALL responsible for about 10-15% all ALL cases in children, it essential to separate special subgroup, nosological entity by biology, poor clinical outcome and resistance therapy. We analyze results treatment 644 patients with T-ALL, registered data base Russian-Byelorussian Research Group over 24 years its work. The initial characteristics...
Background and Purpose:Children with acute myeloid leukemia relapses of are at high risk developing fungal infections need antifungal prophylaxis. This study aimed to compare the efficacy toxicity two different dosage regimens voriconazole (VRCZ) during prophylactic administration in children malignancyand neutropenia. Materials Methods:This prospective was conducted Belarusian Research Center for Pediatric Oncology, Hematology, Immunology fromMay 2017 December 2019. The present included 21...
The detection of genetic markers associated with poor prognosis is crucial to the selection an appropriate treatment plan for B-cell precursor acute lymphoblastic leukemia (BCP-ALL). A hypodiploid karyotype in patients BCP-ALL has unfavorable impact and serves as a criterion stratification into high-risk group. However, survival rates remain poor. Russian protocols childhood do not include risk criteria. In order determine prognostic value clinical characteristics karyotype, we analyzed...
The purpose of the study is to assess frequency occurrence most frequent cytogenetic rearrangements in neuroblastoma (NB) and their correlation with clinical biological characteristics outcome therapy Republic Belarus. Materials methods. 280 patients primary diagnosed NB from 10.10.2007 01.04.2018 were studied. material for was tumor or metastases bone marrow (damage more than 60 %) according criteria protocol. conducted by method fluorescent hybridization situ. Results. such aberrations as...
The article presents an analysis of treatment outcomes pediatric patients with classical Hodgkin's lymphoma (HL) in the Republic Belarus over more than a 20-year period. Patients aged 0 to 18 years HL received therapy according DALHD-90(m) protocol. Therapy modifications involved use systemic chemotherapy OPPA regimen (vincristine, procarbazine, prednisone and doxorubicin) for both sexes dose-reduced involved-field radiotherapy (20 Gy) early or intermediate stage HL. aim our study was...
Diencephalic cachexia (DC ) is a metabolic disorder characterized by decrease in body weight. DC usually occurs the presence of glioma brain tumors extended into optic pathway. These are very aggressive and have poor prognosis. Objective : to analyze clinical course pathway gliomas (OPG s) patients with without . Material Methods. The study included 264 aged 0 18 years an initial diagnosis OPG s registered N.N. Burdenko National Medical Research Center neurosurgery from 01/01/2003...
Diffuse astrocytomas is the major cause of mortality in pediatric neurooncology. Pediatric diffuse are clinically and biologically heterogeneous, they consist distinct subtypes driven by various molecular events. Our aim was to reveal if surrogate signatures reflecting alterations underlying could be prognostic value. The signature determined IHC with antibodies IDH1R132H, p53, BRAF V600E, H3K27trimethylated, ATRX cytogenetics identification deletion CDKN2A FGFR2 fusion. As a result, we...
The incidence of acute lymphoblastic leukemia (ALL) in children Azerbaijan Republic is analyzed for the first time period 1998-2008. ALL was increasing over at an annual increment of3.39 ± 0.9%. Comparative analysis epidemiological data and Belarus has shown a probable neglect cases girls infants aged under 1 year Republic. need creation population cancer register demonstrated.